A phase 1 first-in-human study to evaluate safety and pharmacokinetics of SAR442970 in healthy participants

Trial Identifier: TDR16650
Sponsor: Sanofi
Start Date: January 2022
Study Completion Date: October 2022
Condition: Healthy Volunteers; Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Belgium